The majority of ALK+ ALCL cases (29/33, 88% for pSTAT3-Y705 and 30/33, 91% for pSTAT3-S727) and ALK- ALCL cases (14/22, 64% for pSTAT-Y705 and 19/22, 86% for pSTAT3-S727) expressed pSTAT3-Y705 and pSTAT3-S727 in more than 70% of tumor cells. This evidence concerns the gene ALK and neoplasm.